Clinical Trial Update: Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating enzalutamide plus paclitaxel in stage I-III androgen receptor-positive triple-negative breast cancer has completed enrollme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Taxol (paclitaxel)
• Xtandi (enzalutamide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19